Politecnico di Milano: Project for innovation in Nanotechnology is the winner of ERC Starting grant – Science Business

Politecnico di Milano has won a new Starting Grant issued by the European Research Council (ERC), the European Unions programme that funds scientific research. Funds have been awarded to project B3YOND (acronym for Beyond nanofabrication via nanoscale phase engineering of matter), coordinated by Edoardo Albisetti, which proposes innovations in the nanomanufacturing scene.

The term designates the overall processes and techniques, which underpin the creation of new materials and devices bymanipulating matter with very high precision standards(in the range of one billionth of a millimetre!). These techniques have been an extraordinary stimulus for the development of nanoscience and of nanotechnology over the past decades. They seem to have achieved physical limitations that can only be overcome with original and entirely innovative approaches.

The aim of Albisettis project B3YOND is to innovate the nanotechnological approach by proving the efficacy of a new processing method calledphasic nano-engineering.A heat source of nanometric dimensions is positioned and shifted with the utmost precision on the materials surface in order to induce controlled phasic changes. Phasic manipulation of the material will allow to control its physical properties (e.g., electrical resistivity and conductivity, or magnetism) with unprecedented mastery. This innovative method will be used to develop a new class of artificial nanomaterials and devices for nanoelectronics and spintronics.

The project will be conducted at the Department of Physics, in partnership with PoliFab, Politecnico di Milanos micro and nanomanufacturing centre.

Counting 386 funded projects (amounting to a total of ca. 164,295,670 euro), Politecnico di Milano ranks as the first Italian university for the number of Horizon 2020 projects it has won.

Read this article:
Politecnico di Milano: Project for innovation in Nanotechnology is the winner of ERC Starting grant - Science Business

Global Healthcare Nanotechnology Market With COVID-19 Pandemic Analysis, Growth Rate and Forecast 2020-2025 – The Daily Chronicle

MarketQuest.biz has recently announced a new report entitled Global Healthcare Nanotechnology Market 2020 by Company, Type and Application, Forecast to 2025 offers an overview of the market by giving market data with characteristics and market chain with analysis and developments and increase. The report delivers a comprehensive analysis of the global market which presents the critical analysis of the current state of the global Healthcare Nanotechnology industry, demand for the product, environment for investment, and existing competition. Point by point data about the market players who are holding a fundamental position in the market concerning the business, revenue, open market development, and the temporary courses of action are listed in the market. It covers segments such as competitor segment, product type segment, end use/application segment, and geography segment.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Key Players Profiles:

The report provides present competitive analysis as well as valuable insights to industries or other clients to help them penetrate in a global market. Businesses will get a competitive advantage from this competitive research analysis. The report then covers gives a detailed overview of global Healthcare Nanotechnology industry prime vendors and regional evaluation with forecast period 2020 to 2025. The research focuses on primary and secondary drivers, market share, leading segments, and regional analysis. It also delivers the market competitive landscape and an elementary inspection of the regional growth of the market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/17915

Developments and future opportunities estimated to emerge in the global Healthcare Nanotechnology industry are looked into in this portion of the study. The report also throws light on the competitive landscape, underlining the corporate strategies that the prominent players across various geographies have employed to get ahead in this industry. The research focuses on business consulting, industry chain research, and consumer research to help customers provide non-linear revenue models within this market.

Geographically, this report is segmented into several key regions including North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa). Moreover, the market potential for each geographical region with respect to the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios is analyzed in this report.

This research report also includes profiles of major companies operating in the global market. Some of the prominent players operating in the global Healthcare Nanotechnology market are: Amgen, Merck & Co, UCB, Teva Pharmaceuticals, Sanofi, Abbott, Stryker, Celgene, Roche, Biogen, Smith & Nephew, Shire, Gilead Sciences, Endo International, Leadiant Biosciences, Johnson & Johnson, Pfizer, Ipsen, Kyowa Hakko Kirin, 3M Company

Based on type, the market has been segmented into: Nanomedicine, Nano Medical Devices, Nano Diagnosis, Others

Based on application, the market has been segmented into: Anticancer, CNS Product, Anti-infective, Others

ACCESS FULL REPORT: https://www.marketquest.biz/report/17915/global-healthcare-nanotechnology-market-2020-by-company-type-and-application-forecast-to-2025

Key Features of The Global Market Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

MarketQuest.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. MarketQuest.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. MarketQuest.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketquest.biz

View original post here:
Global Healthcare Nanotechnology Market With COVID-19 Pandemic Analysis, Growth Rate and Forecast 2020-2025 - The Daily Chronicle

2020 Growth Opportunities for Emerging Insulation Materials: Emerging Participants in the Manufacturing, Oil and Gas Industries – PRNewswire

DUBLIN, Sept. 16, 2020 /PRNewswire/ -- The "Growth Opportunities for Emerging Insulation Materials" report has been added to ResearchAndMarkets.com's offering.

Material Advances Enable Development of Cost Efficient, Lightweight, and High-Performance Insulation Systems

Growth Opportunities for Emerging Insulation Materials provides a review of both current and emerging innovations on insulation materials and their potential adoption as cost-efficient and high-performance materials within industries. The research service highlights the key factors that influence R&D and adoption efforts across various geographic regions. It also provides a list of noteworthy innovations and perspectives across the globe and highlights key innovators.

Insulation materials, either in fibrous, cellular or granular form, are adopted across industries such as building and construction, packaging, electronics, consumer goods, energy, manufacturing, oil & gas, aerospace, and automotive. Apart from being a thermal barrier, the materials function as anticorrosion, anti-flame, enhance the durability, and anti-microbial protection. The insulation system comes in the form of solids, liquids or gases, helping to enhance the quality as well as reduce the tendency of energy or heat loss of the insulated product.

However, most of the traditional insulation materials, such as fiberglass, mineral wools, polyurethane foam and aluminum foil have limitations either in the form of its mechanical properties whereby it tends to break or crack when being exposed to extreme surroundings or in its thermal or chemical properties where constant exposure to extreme surroundings reduces its effectiveness. These insulation materials have also contributed to health and environment issues, such inhalation during the application of fiberglass lead could lead to lung diseases as well as the release of chlorine atoms from the polyurethane foam which leads to the thinning of the ozone layer and global warming.

Stakeholders such as the University of California, US Uppsala University, Sweden, Japan Insulation, Japan, and Showa Denko Packaging Co. Ltd., Japan have introduced approaches to develop sustainable alternatives in insulation materials. Across industries, stakeholders, such as Knauf Insulation, US, IMT Mines Als, France, Showa Denko Packaging Co. Ltd., Japan, Terreal Malaysia Sdn Bhd, Malaysia have introduced technologies such as aerogel composites, bio-based composites, aluminum-polyester composites, and ceramic nanofiber and nanocellulose as sustainable alternatives for developing cost-efficient and high-performance insulation technology.

Key Topics Covered:

1.0 Executive Summary1.1 Research Scope1.2 Research Methodology1.3 High Interest on Enhancing the Performance of Insulation Materials throughout the Regions1.4 The Multi-functional Insulation Material Exists in three Different Structures1.5 The Limitations and Opportunities of the Insulation Materials1.6 Factors influencing the Continuous Growth of Insulation Materials1.7 High Performance and Environmental Friendly Features Act as Key Factors for Material Adoption

2.0 Technology Overview2.1 Insulation Material: Definitions2.2 Fibrous Insulation is the most Mature Insulation Technology2.3 Cellular Insulation Exists in both Solid and Liquid Insulation Structures2.4 Granular Insulation has Opportunities for Developing Environmentally Friendly Insulation2.5 Enabling High-performance Reflective Insulation through Composite Technology Development2.6 Gas Insulation Has been Adopted for Enhancing other Types of Insulation Systems

3.0 Industry Assessment3.1 Overview of Insulation Material Technology3.2 Adoption of Aerogel Composite as Environmental Friendly Alternative of Insulation Technology in the Building and Construction Industry3.3 Continuous Interest Within the European Regions on Aerogel and Nanotechnology as Emerging Insulation Technology in Built Environment3.4 Certification for Insulation System Building and Construction Industries Across the North America and Europe Regions3.5 Emerging Participants in Insulating Material in the Building and Construction Industry3.6 Developing High Performance Insulation System from Recyclable Material3.7 Increasing Interest in Developing High Performance Insulation System in the Automotive, Transportation, and Aerospace Industries3.8 Emerging Participants in Insulating Material in the Automotive & Transportation, Aerospace & Defense Industries3.9 Future Potential of Sustainable Alternative of Thermal Insulation3.10 Enhancing the Performance of Insulation Technology in Electronics, Energy & Power System Industries Through Bio-based Composite3.11 Emerging Participants in Innovations in Insulating Material the in Electronic, Energy & Power System Industries3.12 The Future Potential of Lightweight, High Performance Insulation System3.13 High Research Interest of Biocomposite in Insulation System for the Packaging Industry in the European Region3.14 Emerging Participants in Insulating Material in Packaging3.15 Future Adoption of Fibrous Insulation in the Packaging Industry3.16 Gradual Interest in Adoption of Composite and Nanotechnology Alternative Within European Regions in the Manufacturing, Oil and Gas Industries3.17 Emerging Participants in the Manufacturing, Oil and Gas Industries3.18 The Adoption of Lightweight and Energy Saving Insulation System in the Manufacturing Industry

4.0 Innovations Indicators4.1 Patent Activity on Insulation Materials During 2017 to 20194.2 High Interest on Research Studies in China4.3 High Government Funding Across the Regions4.4 High Interest in Product Development Across the Regions4.5 High Interest in Technology Development in the Asia-Pacific Region4.6 Continuous Efforts in Driving Circular Approach in Industries

5.0 Future Prospects for Emerging Insulation5.1 Comparative Analysis of Emerging Insulation Materials in the Next Five Years5.2 Comparative Analysis of Potential Insulation Materials in the Next Ten Years5.3 Emerging Insulation Materials Production- Technology Comparative Analysis

6.0 Growth Opportunities for Insulation Materials6.1 Future Potential in Developing Circular Economy Within the High Performance Insulation Materials6.2 Strategic Imperatives: Critical Success Factors6.3 Growth Opportunities: Enhancing Performance of Thermal Insulating Material Through Composite Technology and Nanotechnology6.4 Increasing Number of Aerogel Composite Innovations and Nanotechnology Across the Regions6.5 Gradual Interest for Bio-based Insulation System Across the Regions6.6 High Interest in Adoption of Recycled Materials as Emerging Insulation Technology in European and Asia-Pacific Regions

7.0 Key Contacts

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/l823wz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original:
2020 Growth Opportunities for Emerging Insulation Materials: Emerging Participants in the Manufacturing, Oil and Gas Industries - PRNewswire

Anatomy of the New Supercapacitor Industry Revealed by IDTechEx Research – PRNewswire

BOSTON, Sept. 17, 2020 /PRNewswire/ -- Surprises abound in the new IDTechEx Research report, "Supercapacitor Markets, Technology Roadmap, Opportunities 2021-2041". In 2010, there were no Chinese manufacturers in the top ten supercapacitor manufacturers. In 2020, 40% of them are Chinese. This has been achieved by world-class R&D, being in one of the largest markets globally, strong investment and government support including protective trading. However, China is not leading in capacitor-supercapacitor hybrids where the USA saw a $7 million follow on order recently.

Raghu Das, CEO of IDTechEx advises, "Supercapacitor manufacturers used to be divided into those making small ones for electronics and those that also made similar flat or cylindrical formats for electrical engineering such as the archetypal 2.7V 3000F cylinder. No longer. A considerable market for even large supercapacitors is rapidly emerging. The first big success with large ones is boxed car stop-starters at around 20Wh, with over five million sold. The number of automakers going for that fit-and-forget, grab more electricity, waste less electricity proposition still increases. The natural extension of this logic is the newly committed adoption of larger supercapacitors for peak-shaving and acceleration boosting at 30-100Wh across the batteries in mild hybrid cars then full hybrid then totally replacing the lithium-ion battery if pure electric cars have not destroyed the hybrid car business by then."

The new large versions appear in trains at 1kWh and 1MWh appears as hospital and data center uninterruptable power supplies that double for peak shaving. It is a long way from small supercapacitors usually made to standards, easy to make and mostly commoditized at prices of 1 cent/F or less. IDTechEx counts 89% of supercapacitor manufacturers making them though Panasonic recently exited. 37% of these are in China because it exports them strongly, its share of the supercapacitor value demand being only 27% because of its giveaway pricing and lateness into car stop-start.

An exception to the commoditization is small supercapacitors in the form of battery-supercapacitor hybrids BSH, aerospace and military ones working at 150C, capacitor-supercapacitor hybrids beating tantalum electrolytics on ripple and one fifth to one tenth of the size and weight and ones in odd formats such as to go in a watch or smart card. Those working at 85C, -40C and 3V as single cells are less common and in demand.

Battery-supercapacitor hybrids (BSH) are almost always lithium-ion capacitors. They offer higher energy density often with effectively infinite cycle life and better charge retention than pure supercapacitors. Energy density several times that of pure EDLC supercapacitors. There is almost always confined to small units for electronics. IDTechEx measures that 24% of supercapacitor manufacturers now have a BSH range and of those 32% are made in China, where they are most successful commercially. China leads the world here, partly because they have so many large BSHs.

Several companies declare their supercapacitors to be "graphene" as a badge of honor. It can mean non-flammable, relatively non-toxic, no use of the volatile, toxic carcinogen acetonitrile, valuably improved series resistance, better voltage and energy density in a pure EDLC all good things justifying a higher price.

Raghu Das adds, "IDTechEx measures that 8.75% of supercapacitor manufacturers now offer graphene versions, up from zero ten years ago. 43% of the manufacturers using graphene are in China so they are ahead in numbers, though certainly not in graphene supercapacitor research, much of which is aimed at the massive emerging market for replacing lithium-ion and lead-acid batteries with highest energy density of 100Wh/kg or more. In research, this is usually achieved by boosted pseudocapacitance though some perfect the technology of the newly commercial 100 Wh/kg lithium-ion supercapacitors. 33% of supercapacitor material research graphene-centric followed by carbon nanotubes then metal organic frameworks."

Large supercapacitors are more difficult to make, more profitable and represent the majority of the addressable market 2021-2041. Unlike small ones, they typically come with integral power electronics for optimal safe operation, microprocessors for intelligent response, often cooling systems. 47.5% of supercapacitor manufacturers now claim to make them, up from few in the past. However, many of those are barely in the business, their web entries being more of a wish list that reality. 34% of these are in China no dominance though it is coming up fast in this respect. This is assisted by the fact that a disproportionate amount of the demand for large supercapacitors is in China with the Government requesting that all parts of trains, buses etc. be made in China. On the other hand, China is badly behind in researching supercapacitor bodywork, smart skin and other radical advances scoped in the IDTechEx Research report, "Supercapacitor Materials and Formats 2020-2040".

Raghu Das predicts, "Acquisitions and mergers will continue. One billion dollar supercapacitor businesses may be created by 2045. If the addressable markets we have analyzed are strongly penetrated, then it will be much earlier. Given past disappointments, our upside forecast currently stands at $7 billion in 2041."

For more information on this report, please visit http://www.IDTechEx.com/supercaps or for the full portfolio of research available from IDTechEx please visit http://www.IDTechEx.com/Research.

IDTechEx guides your strategic business decisions through its Research, Consultancy and Event products, helping you profit from emerging technologies. For more information on IDTechEx Research and Consultancy, contact [emailprotected] or visit http://www.IDTechEx.com.

Media Contact:

Natalie Moreton Digital Marketing Manager [emailprotected] +44(0)1223 812300

SOURCE IDTechEx

Continue reading here:
Anatomy of the New Supercapacitor Industry Revealed by IDTechEx Research - PRNewswire

Video: ‘The Devil All the Time’ | Anatomy of a Scene – The New York Times

NARRATOR: Hi, Im Antonio Campos, and Im the director of The Devil All the Time. So were about 2/3 of the way into the movie, were entering the third act. And Arvin has been spying on this preacher and has figured out that he did something to his stepsister. And so he is coming to get revenge. And one of the things I wanted to convey in this scene is that Arvin isnt a killer. He comes in with the intent of killing him, and in the moment when hes going to shoot, he gets nervous and he sits down, and hes got to muster up the courage to go through with the act. Hes a violent kid, but hes not a killer yet. And so what I wanted to do is I wanted to try and give you two perspectives in this scene, one from the perspective of Teagardin talking to this young man thats come in. You got time for a sinner? Who wants to confess, get something off his chest, and the other, in close up on Arvins face, where we are with Arvin, where were with him, were seeing that hes nervous, and that hes a little anxious. Ive done lustful acts. So we get this angle here, this close-up angle, and thats where were in it with him, and we get to see into his eyes. And then theres the frontal angle, and the frontal, were withholding his eyes. Were seeing it the way that Teagardin sees him. The other thing there is this little technical thing is Teagardin has seen Arvin in church with his grandmother and with his stepsister, but with his hat on, and the angle that hes looking at him, he cant quite identify him. So thats the other reason why this wardrobe was really important for the scene. This is, by far, my favorite scene in the whole movie. And I was so excited for these two characters to come together. And for this force of good and this force of evil to finally meet. And its the beginning of what becomes Arvin coming up against a lot of different evil forces in the story. Its a very long scene, so we really wanted you to feel every single beat. And so this scene took about I think we edited this scene on and off for about nine months. One day I got this girl in my truck and I drove her out to the sticks, and I had my way with her. [SIGHS] She put up a fight? No. And it was really about trying to capture every single detail that these two great actors gave us. I really think that Tom Holland is the greatest actor of his generation. And I think hes so natural, and he conveys such a wonderful humanity, but still manages to capture this kind of danger. And that Rob Pattinson is this kind of mad genius, and you dont know what hes going to give you on the day. And so I had this wonderful footage to work with. And it was really about trying to nail every little micro expression, every gesture. And by doing that, we create this kind of we start building up the tension to the point where then Arvin stands up and, with standing up, he reveals his eyes and reveals his identity to Teagardin. Ive been watching your every move for the last couple weeks. You cant get enough of that Reaster girl, can you? Is that how you did my Lenora, too? And this kind of face off, here, was really this is where it kind of, like, really finely tuned the editing to make sure that every little gesture, once the gun revealed itself, is dangerous for Teagardin. Dont do anything youll regret, son. Why dont you put the gun down, and we can talk all about it? So we really wanted to highlight each beat, and feel every time that Tom gets worked up and Teagardin gets scared. In the sound design, here, you really hear the rattle of the gun. It was just like this this Reaster girl. You get the shake of Arvins hand through the sound of the gun rattling, which is one of these things that we didnt plan on, but when we got into the mix, you really kind of you realize you needed a sound to convey that sort of nervousness, to heighten the nervousness. soul too? Look, I I didnt have nothing to do with that. And then you get this sort of, like, this anger building up. So now Arvin, who came into the scene so, so nervous to go through with the act, is now getting angrier and angrier and angrier. And hes building up the courage to either shoot or not shoot. We dont know yet. We dont know if hes going to change his mind, if Teagardins going to manage to talk his way out of it. I aint going to take the blame for no bastard child. It would ruin me, man. My wife is the editor, Sophia Subercaseaux. She and I always loved every one of Robs deliveries here. She was delusional. Shes crazy. Thats it. Or she was just lonely.

Excerpt from:
Video: 'The Devil All the Time' | Anatomy of a Scene - The New York Times

Anatomy of a record handle year at Scioto Downs – Harness Racing Update

How the rookie team of Joe Morris, Jason Roth and Gabe Prewitt helped post a record handle of $55.3 million at the Columbus, OH track an increase of more than $35 million (and 184 per cent) from 2019.

by Bob Roberts

It almost figures. In a year in which only a sprinkling of fans were on hand to watch the Hambletonian and none will be allowed to take in the Little Brown Jug, another track in central Ohio first with no fans in the stands and then with just a handful of them shattered every wagering record in its 62-year history.

Until this spring, the futuristic-looking Scioto Downs, which opened in 1959 and lost a photo-finish to the St. Lawrence Seaway as a nominee for Outstanding Civil Engineering Achievement, has been a perennial also-ran in the race for North American simulcast dollars.

That all changed when the first-year team of senior vice-president of racing Joe Morris, racing secretary Jason Roth and director of racing Gabe Prewitt put their heads together and turned Scioto Downs into a major player in the signal export business.

In 2019, Scioto Downs totaled $19.5 million in wagering dollars over 90 race dates for an average of $216,666 a program.

This year, it took in $55.3 million over 82 days and nights of betting for an average of $674,390.What made for such a dramatic increase?

Were a new team and we went through things and tried to do whats best for the horsemen and the horseplayer, said Prewitt. Of course, we were lucky to get the jump on the competition.

Scioto Downs COVID-19-delayed opening on May 22 made the south Columbus oval the first track in North America to welcome back pari-mutuel racing.

It allowed us to get our product out there, especially to people that had not previous seen Scioto racing, said Prewitt. It also helped that everybody wanted to enter and race with us. We had a seven to 10 day jump on the competition.

Scioto Downs took full advantage of their calendar advantage by opening with 12 consecutive handles of over $1 million.

Prewitt employed another and rather unique yardstick for measuring success.

I knew we were making an impact when I heard 15 different pronunciations of Scioto the first week of the meeting. There were a lot of new players.

He said that in Morris giving him the green light to try new things, and with Roth putting together attractive racing cards that bettors embraced, the season was off and pacing.

Gabe is a bright guy, Morris told Harness Racing Update. Hes already established a substantial audience for our racing product.

Prewitt focused on managing post times, constructing a wagering menu that attracted fire power, and staying on top of social media.

Scioto Downs kicked off the season with free past performances and live video on its website, as well as placing some of its races on the TVG network.

When the first weekend of racing was over, Scioto had posted its second, third and fourth highest handles in track history.

We revamped the betting menu, completely. We created several carryover opportunities for players, said Prewitt. And my thing is the scheduling of races. Its very important to get your races in the right spots.

Prewitt said he would position himself in a room he called the dungeon (actually the basement tote room) where he would monitor the signals from up to 12 different tracks.

I did everything I could to stay off major signals, he said. I was always looking for a good spot for us, even thinking three or four races down the card. Its like playing poker every night. Youre zigging and zagging to position your races. I learned by watching Dave Bianconi (vice-president of racing at Northfield Park). Hes the best at it.

Sciotos all-time single card betting record ($1.2 million in 1996) fell twice this past season, first with a handle of $1.6 million on May 28, and then $2.09 million seven days later. On the year, there were 15 $1 million handles.

The season was so great that it took Scioto Downs only 17 programs to top the $19.5 million it collected in wagers in all of 2019.

Prewitt pounded the Twitter world each racing night when betting updates and carryover teasers under the banner of #Senditin Army.

He also paired with track announcer Barry Vicroy to handicap the races, not only giving selections, pointing out hot (or cold) drivers and trainers, and studying the odds board for underlays and overlays.

We tried to add to the broadcast, offering horseplayers what they couldnt find on the program pages, said Prewitt. Barry has been around long time. He knows Scioto and its horsemen.

Prewitt knows the pressure will be on next year to maintain or increase Scioto Downs numbers.

Hopefully, well have a few tricks up our sleeves, he said. I think we should do a half-million every time we turn on the lights and race. So, if we race 90 nights, thats a $45 million. And well build on it from there, as we grow the brand.

Read more:
Anatomy of a record handle year at Scioto Downs - Harness Racing Update

X-Men Anatomy: The 5 Weirdest Things About Storm’s Body, Explained – CBR – Comic Book Resources

Marvel's iconic X-Men leader Storm is an Omega-Level mutant, and she can do so much more with her weather-controlling powers making it rain.

To put it mildly, X-Men comics have a tendency to make the backstories of Marvel's mutants intricately complicated, with multiple points that hinge on odd points of continuity and twists of fate. Decades of story twists and turns compound with sci-fi and fantasy mythology to make characters far more deeply complex than you might imagine, and there's no better example of that than Ororo Monroe, the weather-controlling mutant and X-Men leader known as Storm.

While she might just appear to have some control over localized weather patterns, Storm has evolved into a far deeper, stranger character since she was created by Len Wein and Dave Cockrum in 1975's Giant-Size X-Men #1, and her powers have changed along with her.

RELATED:A Powerful X-Men Villain Has Returned... As A Talk Show Host!?

Storm's ability to control the weather is certainly considerable, and it usually puts her in the top tier of most any given X-Men squad she serves on. Controlling all of that power can be difficult, but aiding her in the task is an extension of her mutant abilities that is not quite as obvious as hurling lightning or whipping up rainstorms: she feels an almost spiritual connection with the planet and its weather cycles, physically perceiving them as energy patterns.

Storm's senses allow her to predict the weather even when she does not influence it and sense any abnormalities in its rhythm. This can have the side effect of inflicting discomfort on her when the Earth is in pain, but she never views her connection as a hindrance. Her claustrophobia is in part so traumatic because it cuts her off from the world around her, so it's understandable why losing such a connection would be anxiety-inducing.

Even with her connection to the planet, Storm's powers don't just work exclusively on Earth. Her powers have been accessible on other worlds, in the vacuum of space and even on the astral plane. The environment very seldom negates Storm's capacity to produce weather phenomena on a whim, although it can prove a limiting factor where she is not as powerful as usual.

This means that Storm maintains her ability to hurl lightning even while underground or to create billowing rainstorms within the constricted confines of an indoor environment. She frequently makes storm clouds just small enough to water her plants, a convenient trick for an avid gardener like Ororo.

See more here:
X-Men Anatomy: The 5 Weirdest Things About Storm's Body, Explained - CBR - Comic Book Resources

The Revolutionary Royalist Demonstrates the Anatomical Cause of a Psychiatric Illness – Psychiatric Times

Looking Back to Look Forward

This MONTH in PSYCHIATRY

SERIES EDITOR: Gregory Eghigian, PhD

Revolutionary Paris was the center of things in more ways than one. Dr Phillipe Pinel, a child of the Enlightenment, laid down principles of psychiatry that many still follow today. Pinel, followed by his epigone Dr Jean-tienne Dominique Esquirol, believed that the root cause of mental illness lay in the environment. Patients therefore required moral treatment, based on the belief that individuals exhibiting mental illness could be carefully re-educated in the humane and orderly regime of a reformed asylum.

Paris, a city associated with hedonism, indulgence, creativity and apostasy, was the home of a new psychiatric illness: generalised paresis of the insane (GPI). It was characterised by grandiose thinking, disorganized behaviour, emotional outbursts, and flights of wild fantasy culminating in collapse, rapid dementia, and paralysis. Patients were unable to care for themselves, dying mostly in lunatic asylums.

The Pinel school attributed GPI to environmental causes. But then one of the most original and unusual characters in the history of psychiatry arrived on the scene and challenged the environmental hypothesis. His name was Antoine Laurent Jesse Bayle. As a Royalist, he was swimming against the political currents of the day and a possible candidate for persecution. He had trained under Dr RenLaennec, a proponent of the then-unfashionable anatomico-pathological view and inventor of the stethoscope.

Bayle went into psychiatry at the Royal Asylum for the Insane at Charenton in 1818. Up to one-third of the male patients had GPI, and it was clear that moral therapy was not going to provide a solution to their illness.

On November 21, 1822, Bayle presented his doctorate, describing 6 autopsy cases of GPI with gross thickening of the meninges and inflammation of the vasculature. GPI, he stated, was due to chronic meningo-vascular arachnoiditis. Its cause was anatomical, not environmental or moral. This extraordinary discovery was made by a young man at the level of what today would be regarded as internship. He was precociousness personified.

The significance of Bayles finding cannot be understated. It was the first description of the visible and definable neuropathological cause of a psychiatric disease and deserves to go down in history as the fons et origo of the scientific roots of the discipline.1

In 1825, Bayle pushed the envelope by claiming that all insanity was due to chronic meningeal inflammation. The response from his peers was critical, if not caustic. Dr tienne-Jean Georget (making sure he did not leave anything out) condemned Bayle of being shallow, impertinent, showing exaggerated pretension, immature, reaching impossible conclusions, and having a rash nature.

Undeterred, Bayle went on to write up 100 autopsy findings in 1826, warning that the moral school could lead one astray by making one neglect the organic cause of diseases, by focusing too exclusively on derangements of function.

At the age of 27 Bayle walked away from psychiatry to become an archivist and sank into obscurity.

If the environmentalists won the battle, it was a short-lived victory; the war was eventually lostdecisively. Bayle had correctly anticipated a paradigm shift. Within decades, the anatomico-pathological model ruled supreme. The center of psychiatric gravity accordingly moved to the Germanic world, and French psychiatry was never the same.

Dr Kaplan wrote about syphilis in his book The Exceptional Brain and How it Changed the World. He is Clinical Associate Professor at the Graduate School of Medicine, Wollongong University and Research Fellow, History Department, Stellenbosch University, South Africa.

1. Kaplan RM. Syphilis, sex and psychiatry, 1789-1925: Part 1.Australas Psychiatry. 2010;18(1):17-21.

View post:
The Revolutionary Royalist Demonstrates the Anatomical Cause of a Psychiatric Illness - Psychiatric Times

‘Grey’s Anatomy’ Season 17 to premiere Nov. 12 – UPI News

Sept. 18 (UPI) -- Grey's Anatomy will return for a 17th season in November.

ABC announced a premiere date, Nov. 12, for Season 17 in a press release Thursday.

The two-hour season premiere will air Nov. 12 at 9 p.m. EDT. Season 4 of the Grey's Anatomy spinoff Station 19 will premiere the same night at 8 p.m.

ABC shared a moving poster for Grey's Anatomy Season 17 on Twitter featuring Ellen Pompeo as her character. Dr. Meredith Grey.

"Sometimes... we all need saving," the tagline reads.

The network also released a teaser for the season featuring Dr. Teddy Altman (Kim Raver) and Dr. Owen Hunt (Kevin McKidd).

ABC also announced premiere dates for other fall shows. The Good Doctor Season 4 premieres Nov. 2 at 10 p.m. EDT, while David E. Kelley's new series Big Sky will make its debut Nov. 17 at 10:01 p.m.

"Our fall schedule is now complete with a dynamic lineup of new and returning drama series," ABC Entertainment president Karey Burke said. "From fan-favorite shows like Grey's Anatomy and The Good Doctor to David E. Kelley's thrilling new drama Big Sky, our strength is in our storytelling, and we could not be more energized to bring these compelling series to our viewers."

Read this article:
'Grey's Anatomy' Season 17 to premiere Nov. 12 - UPI News

How Tom Holland Seeks Revenge in The Devil All the Time – The New York Times

NARRATOR: Hi, Im Antonio Campos, and Im the director of The Devil All the Time. So were about 2/3 of the way into the movie, were entering the third act. And Arvin has been spying on this preacher and has figured out that he did something to his stepsister. And so he is coming to get revenge. And one of the things I wanted to convey in this scene is that Arvin isnt a killer. He comes in with the intent of killing him, and in the moment when hes going to shoot, he gets nervous and he sits down, and hes got to muster up the courage to go through with the act. Hes a violent kid, but hes not a killer yet. And so what I wanted to do is I wanted to try and give you two perspectives in this scene, one from the perspective of Teagardin talking to this young man thats come in. You got time for a sinner? Who wants to confess, get something off his chest, and the other, in close up on Arvins face, where we are with Arvin, where were with him, were seeing that hes nervous, and that hes a little anxious. Ive done lustful acts. So we get this angle here, this close-up angle, and thats where were in it with him, and we get to see into his eyes. And then theres the frontal angle, and the frontal, were withholding his eyes. Were seeing it the way that Teagardin sees him. The other thing there is this little technical thing is Teagardin has seen Arvin in church with his grandmother and with his stepsister, but with his hat on, and the angle that hes looking at him, he cant quite identify him. So thats the other reason why this wardrobe was really important for the scene. This is, by far, my favorite scene in the whole movie. And I was so excited for these two characters to come together. And for this force of good and this force of evil to finally meet. And its the beginning of what becomes Arvin coming up against a lot of different evil forces in the story. Its a very long scene, so we really wanted you to feel every single beat. And so this scene took about I think we edited this scene on and off for about nine months. One day I got this girl in my truck and I drove her out to the sticks, and I had my way with her. [SIGHS] She put up a fight? No. And it was really about trying to capture every single detail that these two great actors gave us. I really think that Tom Holland is the greatest actor of his generation. And I think hes so natural, and he conveys such a wonderful humanity, but still manages to capture this kind of danger. And that Rob Pattinson is this kind of mad genius, and you dont know what hes going to give you on the day. And so I had this wonderful footage to work with. And it was really about trying to nail every little micro expression, every gesture. And by doing that, we create this kind of we start building up the tension to the point where then Arvin stands up and, with standing up, he reveals his eyes and reveals his identity to Teagardin. Ive been watching your every move for the last couple weeks. You cant get enough of that Reaster girl, can you? Is that how you did my Lenora, too? And this kind of face off, here, was really this is where it kind of, like, really finely tuned the editing to make sure that every little gesture, once the gun revealed itself, is dangerous for Teagardin. Dont do anything youll regret, son. Why dont you put the gun down, and we can talk all about it? So we really wanted to highlight each beat, and feel every time that Tom gets worked up and Teagardin gets scared. In the sound design, here, you really hear the rattle of the gun. It was just like this this Reaster girl. You get the shake of Arvins hand through the sound of the gun rattling, which is one of these things that we didnt plan on, but when we got into the mix, you really kind of you realize you needed a sound to convey that sort of nervousness, to heighten the nervousness. soul too? Look, I I didnt have nothing to do with that. And then you get this sort of, like, this anger building up. So now Arvin, who came into the scene so, so nervous to go through with the act, is now getting angrier and angrier and angrier. And hes building up the courage to either shoot or not shoot. We dont know yet. We dont know if hes going to change his mind, if Teagardins going to manage to talk his way out of it. I aint going to take the blame for no bastard child. It would ruin me, man. My wife is the editor, Sophia Subercaseaux. She and I always loved every one of Robs deliveries here. She was delusional. Shes crazy. Thats it. Or she was just lonely.

Visit link:
How Tom Holland Seeks Revenge in The Devil All the Time - The New York Times

Anatomy of a Wind Turbine: The Eco-Friendly Power Solution – Indiainfoline

We imagine your first encounter with a wind turbine was through the window of your car as you zip down a remote highway. Wind turbines are unforgettable because of their large and impressive stature and are emblematic of the widespread global adoption of this power source as a means to generate more sustainable energy solutions for communities.

India has been at the forefront of renewableenergy revolution and has emerged as the one of the world's largest and most competitive markets for cleanenergy innovations. Wind power saw a stable growth in the country over the past few decades, and India currently ranks fourth in the global wind energy capacity ranking.

TwoIEEE Power and Energy Society (PES)members, Pouyan Pourbeik and Nicholas Miller, explain how wind power technology works, and why it is so important.

What is a wind turbine?In simplest terms, a wind turbine is a mechanical machine that converts the kinetic energy of wind into mechanical rotational energy that can be used to do some work, says Pourbeik.

Utilizing the natural resource, wind, as a source of energy production is not a new technological practice. In fact, wind turbines have been developed in various ways for several centuries. Pourbeik says that the first recorded wind turbine dates back to the seventh century in Iran and was used to grind grain and pump water from wells.

Todays modern wind turbines are used to run electrical machines that then convert the rotational mechanical energy into electrical energy that can serve the electrical needs of residential homes, commercial buildings and industry, says Pourbeik.

How is wind power a sustainable technology?

Wind turbines are sustainable because of the power conversion process; by tapping into the wind, the process is cleaner than having to mine or burn material that creates massive amounts of emissions as a result. Wind energy is a solution to reducing those carbon emissions, eliminating other forms of pollution in the air, and eventually moving away from traditional methods that have the opposite effect on our planet.

Another benefit of wind power is that this source of energy is free and bountiful. When I lecture on wind turbine basics, I often start with the statement a wind turbine is a device that converts the kinetic energy in wind/moving air into money, says Miller. The fact that there is electric power generated is incidental.

You cant afford to build a wind turbine that captures all of the available energy all the time, says Miller.

What are the challenges of wind energy?

Every technology comes with its own set of challenges that engineers are equipped to solve. Integration into pre-existing power grids and gaining general public awareness of the technology as a sustainable tool are the current hurdles Pourbeik and Miller face as power engineers.

There are challenges with engineering such systems and reliably integrating them into the world-wide electric infrastructure but that is what makes the current technical environment in the field of power and energy engineering so exciting, says Pourbeik.

One of those challenges to the energy grid is energy storage and reliability. Traditionally, when a customer demands electric power, the generation and the power grid is capable of meeting that demand. But with the advent and explosive growth of wind and solar power, it is Mother Nature who decides when the electric power will be supplied, not the consumer, says Miller.

Since the birth of the electric power system in the late 19th and early 20th century, energy has been converted from mechanical energy to electrical energy through the use of rotating electrical machines, which are directly connected to the bulk power grid, explains Pourbeik. These conventional machines run at a constant speed, which means that the frequency of the electrical power they produce is also constant.

Because wind turbine speed is constantly changing due to the wind, power engineers must figure out a way to efficiently convert the wind energy to mechanical rotating energy. The solution is a rotating electrical machine connected to the wind turbine that runs at a wide range of speeds.

So to interface the machine (running at different speeds) to the bulk electrical power system (which has a fixed frequency) one needs to use a power-electronic converter interface, says Pourbeik. Thus, the electrical behavior of the power generating device becomes very different as seen from the grid.

While power-electronic converters have been used in other ways, they have never been used at such a large scale as they are now to connect the heart of wind power plants to the grid. Over the last few decades, the power and energy industry has been learning how to utilize this technology in the most reliable way possible.

Pouyan and I have worked through the first stages of the revolution, says Miller. Since the turn of the century, we have watched (and participated) as innovations in technology, markets, regulation and understanding have steadily moved the challenge out. Today, we (the U.S. and other world grids) regularly operate at levels of wind and solar generation that we thought would be nearly impossible or wouldnt happen for decades into the future.

IEEE PES and the renewable integration community have a large focus on how to make the grid work in a reliable, safe, clean and affordable fashion. But Pourbeik and Miller are hopeful about the future of sustainable energy and the technology being developed.

We are continuing to move at an astonishing rate, adding innovations on all those fronts, says Miller. Very honestly, there has never been a better, more exciting time to be a power engineer.

See the original post:
Anatomy of a Wind Turbine: The Eco-Friendly Power Solution - Indiainfoline

Anatomy of the New Supercapacitor Industry – ValueWalk

Surprises abound in the new IDTechEx Research report, Supercapacitor Markets, Technology Roadmap, Opportunities 2021-2041. In 2010, there were no Chinese manufacturers in the top ten supercapacitor manufacturers. In 2020, 40% of them are Chinese. This has been achieved by world-class R&D, being in one of the largest markets globally, strong investment and government support including protective trading. However, China is not leading in capacitor-supercapacitor hybrids where the USA saw a $7 million follow on order recently.

Get the entire 10-part series on Charlie Munger in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues.

Q2 2020 hedge fund letters, conferences and more

Raghu Das, CEO of IDTechEx advises, Supercapacitor manufacturers used to be divided into those making small ones for electronics and those that also made similar flat or cylindrical formats for electrical engineering such as the archetypal 2.7V 3000F cylinder. No longer. A considerable market for even large supercapacitors is rapidly emerging. The first big success with large ones is boxed car stop-starters at around 20Wh, with over five million sold. The number of auto makers going for that fit-and-forget, grab more electricity, waste less electricity proposition still increases. The natural extension of this logic is the newly committed adoption of larger supercapacitors for peak-shaving and acceleration boosting at 30-100Wh across the batteries in mild hybrid cars then full hybrid then totally replacing the lithium-ion battery if pure electric cars have not destroyed the hybrid car business by then.

The Canyon Distressed Opportunity Fund III has been finding more and more opportunities to invest amid the coronavirus pandemic. In their recent letter to investors, which was reviewed by ValueWalk, the Canyon team noted that one of the main features of COVID-19 has been the way it has affected so many aspects of our lives. Read More

The new large versions appear in trains at 1kWh and 1MWh appears as hospital and data centre uninterruptable power supplies that double for peak shaving. It is a long way from small supercapacitors usually made to standards, easy to make and mostly commoditised at prices of 1 cent/F or less. IDTechEx counts 89% of supercapacitor manufacturers making them though Panasonic recently exited. 37% of these are in China because it exports them strongly, its share of the supercapacitor value demand being only 27% because of its giveaway pricing and lateness into car stop-start.

An exception to the commoditisation is small supercapacitors in the form of battery-supercapacitor hybrids BSH, aerospace and military ones working at 150C, capacitor-supercapacitor hybrids beating tantalum electrolytics on ripple and one fifth to one tenth of the size and weight and ones in odd formats such as to go in a watch or smart card. Those working at 85C, -40C and 3V as single cells are less common and in demand.

Battery-supercapacitor hybrids (BSH) are almost always lithium-ion capacitors. They offer higher energy density often with effectively infinite cycle life and better charge retention than pure supercapacitors. Energy density several times that of pure EDLC supercapacitors. There is almost always confined to small units for electronics. IDTechEx measures that 24% of supercapacitor manufacturers now have a BSH range and of those 32% are made in China, where they are most successful commercially. China leads the world here, partly because they have so many large BSHs.

Several companies declare their supercapacitors to be graphene as a badge of honour. It can mean non-flammable, relatively non-toxic, no use of the volatile, toxic carcinogen acetonitrile, valuably improved series resistance, better voltage and energy density in a pure EDLC all good things justifying higher price.

Raghu Das adds, IDTechEx measures that 8.75% of supercapacitor manufacturers now offer graphene versions, up from zero ten years ago. 43% of the manufacturers using graphene are in China so they are ahead in numbers, though certainly not in graphene supercapacitor research, much of which is aimed at the massive emerging market for replacing lithium-ion and lead-acid batteries with highest energy density of 100Wh/kg or more. In research, this is usually achieved by boosted pseudocapacitance though some perfect the technology of the newly commercial 100 Wh/kg lithium-ion supercapacitors. 33% of supercapacitor material research graphene-centric followed by carbon nanotubes then metal organic frameworks.

Large supercapacitors are more difficult to make, more profitable and represent the majority of the addressable market 2021-2041. Unlike small ones, they typically come with integral power electronics for optimal safe operation, microprocessors for intelligent response, often cooling systems. 47.5% of supercapacitor manufacturers now claim to make them, up from few in the past. However, many of those are barely in the business, their web entries being more of a wish list that reality. 34% of these are in China no dominance though it is coming up fast in this respect. This is assisted by the fact that a disproportionate amount of the demand for large supercapacitors is in China with the Government requesting that all parts of trains, buses etc. be made in China. On the other hand, China is badly behind in researching supercapacitor bodywork, smart skin and other radical advances scoped in the IDTechEx Research report, Supercapacitor Materials and Formats 2020-2040.

Raghu Das predicts, Acquisitions and mergers will continue. One billion dollar supercapacitor businesses may be created by 2045. If the addressable markets we have analysed are strongly penetrated, then it will be much earlier. Given past disappointments, our upside forecast currently stands at $7 billion in 2041.

Visit link:
Anatomy of the New Supercapacitor Industry - ValueWalk

ABC’s Fall TV 2020 Premiere Date Schedule: Grey’s Anatomy, Good Doctor, A Million Little Things, and More – TV Guide

Now Playing100 Best Shows: The Best Streaming Shows

Summer 2020 is finally behind us, and you know what that means: It's officially time to dig back into fall TV. ABC has already announced plenty of premiere dates forits fall schedule, and the lineup is stacked with non-scripted programming.

WhileDancing With the Starsis officially underway after premiering on Monday, Sept. 14, and you're probably still reeling from the Carole Baskin of it all, there's still more to come throughout the rest of September and into October and November.The Bachelorettehas, to the surprise of no one, sparked a ton of questions and rumors as production on the upcoming season has progressed. Less dramatic is the premiere of theSupermarket Sweeprevival, hosted byLeslie Jones, which also has an official premiere date. These shows all join the previously announced comedy lineup, which includes season premieres forblack-ish,The Goldbergs, andThe Conners.

The lineup doesn't include the recently canceledStumptown, but we do finally have dates for some of our other faves likeThe Good DoctorandGrey's Anatomy.David E. Kelley's new seriesBig Sky also got a fall premiere date, butKyra Sedgwick's comedyCall Your Motheris still to be determined.

Check out ABC's premiere schedule below, andlearn more about the network's 2020-2021 fall lineup here. If you want to see what else is coming back this fall across the other major networks, head here. New shows are in ALL CAPS.

Monday, Sept. 14Dancing with the Stars(8/7c)

Thursday, Sept. 248/7c: Celebrity Family Feud9/8c: Press Your Luck10/9c: Match Game

Tuesday, Oct. 138/7c: The Bachelorette

Friday, Oct. 168/7c: Shark Tank

Sunday, Oct. 187/6c: America's Funniest Home Videos8/7c: SUPERMARKET SWEEP9/8c: Who Wants To Be A Millionaire10/9c: Card Sharks

Wednesday, Oct. 218/7c:The Goldbergs(premiering with two back-to-back episodes)9/8c:The Conners9:30/8:30c:black-ish

Wednesday, Oct. 288:30/7:30c:American Housewife

Monday, Nov. 210/9c: The Good Doctor

Thursday, Nov. 128/7c: Station 199/8c: Grey's Anatomy (two-hour premiere)

Tuesday, Nov. 1710/9c: Big Sky (series premiere)

Wednesday, Nov. 1810/9c: For Life

Thursday, Nov. 1910/9c: A Million Little Things

PHOTOS:Dancing with the Stars: 25 Most Shocking Moments

Read more:
ABC's Fall TV 2020 Premiere Date Schedule: Grey's Anatomy, Good Doctor, A Million Little Things, and More - TV Guide

Study Highlights Clinical Features and Prevalence of… : Neurology Today – LWW Journals

Article In Brief

Double-seronegative myasthenia gravis patients (DNMG), who were antibody positive for both lipoprotein receptor-related protein 4 and agrin, had a more severe case of the condition than those who were antibody-negative. Experts discuss whether currently approved treatment options would also benefit DNMG patients who are positive for both antibodies.

Patients with double-seronegative myasthenia gravis (DNMG) who were antibody positive for both lipoprotein receptor-related protein 4 (LRP4) and agrin had a more severe case of the condition than those were antibody-negative, a multicenter study found.

Patients identified as DNMG lack autoantibodies against the nicotinic acetylcholine receptor (AChR) detected in about 80 percent of patients with generalized MG and to muscle-specific tyrosine kinase (MuSK) found in about 10 percent of generalized MG cases.

Whether currently approved treatment options would also benefit these DNMG patients who are positive for LRP4 and agrin would be worth examining in future studies, neuromuscular experts not involved with the current research told Neurology Today.

In the study published in the September issue of Muscle and Nerve, the investigators, led by Michael H. Rivner, MD, the Charbonnier professor of neurology and director of electrodiagnostic medicine laboratory at Augusta University in Georgia, and colleagues, sought to identify the clinical characteristics, prognosis, and prevalence of LRP4 or agrin-antibodies in DNMG patients from 16 clinical sites.

Of 181 DNMG patients, 14.9 percent were positive for either agrin or LRP4, and 12.7 percent were positive for both LRP4 and agrin antibodies.

Although antibody-positive patients had more severe disease than antibody-negative patients, most DNMG patients responded to standard therapy regardless of their antibody status, the researchers reported.

Also, 43 percent of antibody-negative patients had ocular or mild generalized symptoms compared with 69 percent of antibody-positive patients, the investigators found.

These findings are similar to the rates seen in other reports, the researchers noted. Although patients positive for both [LRP4 and agrin] have been reported previously, this is not a commonly observed finding among the few patients who have been tested for both antibodies, the authors wrote.

There have been a few papers published in the literature that have looked at MG patients, that were positive for LRP4 and agrin, but the numbers of patients studied were limited, Dr. Rivner told Neurology Today.

The prevalence of LRP4 antibodies have been very variable in previous studies reported in the literature. Most of these studies were relatively small; only one study had a sizable number of patients.

Dr. Rivner noted that the prevalence of LRP4 antibodies in other studies in patients with myasthenia gravis ranged from less than 1 percent to as high as 40 percent. For double negative MG patients, the prevalence rate varied from less than 1 percent to as high as 50 percent. So pretty much, we really didn't know what the prevalence was.

If you look at the situation with agrin, we knew even less, he added.

Finding these antibodies likely indicates that these patients have a more severe course of the disease, noted Dr. Rivner. Of course, finding a new antibody makes it a little bit easier to take care of these patients because a lot of times, patients present with vague symptoms. We can do some physiological testing, which is helpful, but finding an antibody is also helpful in diagnosing the disease.

In the current analysis, all patients showed clinical symptoms of MG, received either rituximab within six months of their antibody test or intravenous immunoglobulin or plasma exchange within six weeks of their antibody test.

Nearly 90 percent of patients who tested positive for LRP4 or agrin developed generalized MG. However, after an average follow-up period of 11 years, 81.5 percent of these antibody-positive patients, who received standard MG therapy, improved on MG rating scales.

I think the most interesting thing and something that we didn't knowwas that patients who had antibodies for LRP4 or agrin, had a more severe form of myasthenia than patients who did not have antibodies. We termed these as quad-negative patients because they did not have antibodies to acetylcholine, MuSK, LRP4, and agrin, and those patients had a milder course of the disease than the patients who had antibodies to LRP4 and agrin, Dr. Rivner told Neurology Today.

While the researchers had access to clinical exam data on antibody-positive patients, Dr. Rivner said, we don't have physical exam findings on antibody-negative patients.

Having information from exams would allow the investigators to compare antibody positive and negative patients, Dr. Rivner said.

The study focuses on the clinical presentation of patients with agrin and LRP4 antibodies in a more systematic way, said Julie Rowin, MD, FAAN, DABMA, of Integrative Neurology in Westchester, IL.

It is interesting that the majority of patients in this study had both LRP4 and agrin antibodies (85 percent), Dr. Rowin told Neurology Today in an email. The coexistence of these two antibodies in MG patients had not really been assessed previously. Having said that, LRP4 interacts with agrin forming a complex with MuSK, so there are structural relationships between these proteins.

In addition, Dr. Rowin said, agrin and LRP4 antibodies are present in other neurological disorders such as ALS and MS as well as some AChR and MuSK seropositive patients, so it remains unclear at this point if these antibodies are directly involved in the pathogenesis of MG or are a secondary result of the neuromuscular junction damage that occurs in myasthenic disorders.

Dr. Rowin said that both the LRP4/agrin antibody-positive patients and the double seronegative patients responded equally well to standard therapy and that the paper does not offer any indication that treatment decisions should be impacted by a patients LRP4/agrin antibody status. The role of newer therapeutic options in these patients (e.g., complement inhibition) cannot be gleaned from this study, she added.

Although the authors recommend testing for LRP4/agrin antibodies in double seronegative patients, at this point, there doesn't appear to be a compelling reason to do this routinely, as the response to standard therapy is no different for LRP4/agrin positive patients versus seronegative patients; the two groups are comparable in the response to standard medical management, Dr. Rowin said.

The current literature consists mainly of case reports, and the data are inconsistent, but this paper provides us with a more rigorous and consistent approach, agreed Alejandro Tobon, MD, chief of the neurology section at South Texas Veterans Health Care System.

It was interesting that most patients that tested positive were positive for both LRP4 and agrin, Dr. Tobon said. Most of the case reports that we've seen in the literature were either patients that were LRP4 positive or agrin positive and the fact that they found that most patients had both raises interesting questions. We still don't know much, but it may have implications in the future for better diagnostic testing and for treatment possibilities.

For example, we have FDA-approved medications such as eculizumab for MG, which is approved only for AChR antibody-positive myasthenia gravis, said Dr. Tobon. Now that we have identified another group of patients that are antibody positive, it will be interesting to determine through research whether a medication like eculizumab or others in development affect treatment in this group. It opens the door to see other treatment options that are not routinely available for seronegative myasthenia patients.

Dr. Rivner disclosed relationships with Allergan, Alexion, Ra Pharmaceuticals, Cytokinetics, Catalyst, Biohaven, UCB, Momenta, Shire Takeda, Mallinckrodt, Seikagaku, Grifols, and Orion. Dr. Rowin disclosed relationships with AveXis and Novartis. Dr. Tobon did not report any conflicts of interest.

Originally posted here:
Study Highlights Clinical Features and Prevalence of... : Neurology Today - LWW Journals

Extended-Release Amantadine Improves Walking Speed in Patients With MS – Neurology Advisor

The following article is part of conference coverage from the 8th Joint American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) MSVirtual2020 event. Neurology Advisors staff will be reporting breaking news associated with research conducted by leading experts in neurology. .

The extended release capsule form of amantadine (ADS-5102), FDA approved as Gocovri for the treatment of dyskinesia in Parkinson disease, displayed a dose-response for both tolerability and efficacy. This suggests potential clinically meaningful benefits for walking speed in patients with multiple sclerosis (MS), according to study results presented at the 8th Joint American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) MSVirtual2020 event, held September 11-13, 2020.

The pharmacokinetic profile of ADS-5102 enables once-daily bedtime dosing, providing a higher drug concentration throughout the day and lower concentrations at night. This phase 3 study, INROADS, was designed to assess the benefits of ADS-5102 on walking speed in patients with MS, as well as the drugs safety.

The INROADS study began with 4 weeks of placebo followed by 12 weeks of double-blind testing. Of 594 patients from Canada or the United States with MS and walking impairment, 560 were randomly assigned, 1:1:1, to placebo (n=186), 274 mg ADS-5102 (n=185), or 137 mg ADS-5102 (n=187). The primary study endpoint was the proportion at week 16 showing a statistically significant increase in response rate. This was defined as 20% improvement from baseline in timed 25-foot walk [T25FW], measured in feet/second, compared to performance on placebo. Patients without an assessment at week 16 were considered nonresponders.

At week 16, 274 mg ADS-5102 displayed 21.1% (P =.01) improvement, 137 mg ADS-5102 displayed 17.6% (P =.08) improvement, and placebo displayed 11.3% improvement in response rate. Results indicated that 274 mg ADS-5102 met the primary objective of a statistically significantly greater response rate vs placebo. Among the subjects completing the study, response rates were 11.9% for placebo vs 28.3% (P <.001) for 274 mg, and 19.6% (P =.049) for 137 mg. Most observed adverse events (AEs) included dry mouth, peripheral edema, constipation, urinary tract infection, fall, and insomnia. These AEs led study researchers to discontinue the study for 20.5% of 274 mg participants, 6.4% of 137 mg participants, and 3.8% of placebo participants.

Study investigators concluded, INROADS met its primary objective of showing clinically meaningful benefit in MS walking speed for 274 mg ADS-5102. A dose-response was seen for both efficacy and tolerability. They added that observed AEs matched the known safety profile of amantadine, and that results indicated that ADS-5102 may help improve walking in patients in MS, particularly those who have tried and discontinued dalfampridine.

Visit Neurology Advisors conference section for continuous coverage from the ACTRIMS/ECTRIMS MSVirtual2020 Forum.

Reference

Cohen J, Cameron M, Goldman M, et al. Phase 3 Study Results Assessing the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in MS Patients With Walking Impairment. Presented at: 8th Joint American Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis MSVirtual2020 event; September 11-13, 2020; Poster P0225.

More:
Extended-Release Amantadine Improves Walking Speed in Patients With MS - Neurology Advisor

Gutmann receives award from neurological association – Washington University School of Medicine in St. Louis

Visit the News Hub

Honored for work on role of immune system in brain tumors

Gutmann

David H. Gutmann, MD, PhD, the Donald O. Schnuck Family Professor and vice chair for research affairs in the Department of Neurology at Washington University School of Medicine in St. Louis, has received the George W. Jacoby Award from the American Neurological Association for his discoveries on the role of the immune system in brain tumors.

The award is given once every three years to a scientist who has done especially noteworthy experimental work on any neurologic or psychiatric subject. Gutmann was recognized for a body of research showing that two kinds of immune cells microglia and T cells control the formation and growth of brain tumors in mice, similar to those arising in children with neurofibromatosis type 1 (NF1). The findings could lead to new ways to help doctors predict which brain tumors are most likely to become life-threatening, and opens up new avenues to prevent or treat brain tumors.

Gutmann will accept the award at the American Neurological Association annual meeting in October, which will be held online.

View post:
Gutmann receives award from neurological association - Washington University School of Medicine in St. Louis

Stroke patients with COVID-19 have increased inflammation, stroke severity and death – The Mix

This study of ischemic stroke patients is the first to associate the neutrophil-lymphocyte ratio in patients with COVID-19 and ischemic stroke and stroke severity.

Chen Lin, M.D.,assistant professor in the UAB Department of NeurologyStroke patients who also have COVID-19 showed increased systemic inflammation, a more serious stroke severity and a much higher rate of death, compared to stroke patients who did not have COVID-19, according to University of Alabama at Birmingham research led by Chen Lin, M.D., an assistant professor in the UAB Department of Neurology.

The research, published in the journal Brain, Behavior & Immunity Health, is a retrospective, observational, cross-sectional study of 60 ischemic stroke patients admitted to UAB Hospital between late March and early May 2020. Ischemic stroke occurs when a blood vessel for the brain is blocked by a clot, depriving some brain tissue of oxygen. All patients were tested for COVID-19 at admission.

The UAB researchers mined electronic medical records of confirmed stroke cases for information on age, gender and race; clinical variables; laboratory data, including complete blood counts, blood chemistry and coagulation tests; and outcomes, including death, length of hospital stay and condition at discharge.

The ratio of the number of neutrophils to the number of lymphocytes, or the NLR, as calculated from blood count data, served as an index of the systemic inflammatory response. While other researchers have associated NLR with COVID-19 disease severity, refractory disease and even as an independent factor for mortality, our study is the first to associate the NLR in patients with COVID-19 and ischemic stroke and stroke severity, Lin said.

Of the 60 hospitalized patients with acute systemic stroke, nine were positive for a COVID-19 infection.

The UAB research had four major findings. First, patients who were positive for COVID-19 presented with a more severe neurological deficit at admission, as measured by the National Institutes of Health Stroke Scale, or NIHSS, score, which averaged 18.4. Second, all patients with an NIHSS score higher than 4 including uninfected patients had a significantly higher NLR than those with lower scores. The NIHSS is used to predict lesion size and gauge stroke severity.

Third, patients with COVID-19 had an increased inflammatory response, including significantly higher neutrophil counts, lower lymphocyte counts and an increased NLR, compared with uninfected patients. Finally, stroke patients with COVID-19 had a significantly higher mortality rate 44.4 percent, versus 7.6 percent for uninfected stroke patients.

Two other studies this year have reported clinical and laboratory differences in ischemic stroke patients with and without COVID-19, Lin says, but neither addressed racial differences or NLR differences between groups.

Diana M. Lin, UAB Department of PathologyWe have reported the first experience within the Stroke Belt of the Southern United States, which has the highest proportion of African American stroke patients, said Lin, who is also the director of the Stroke Recovery Clinic in the UAB Division of Cerebrovascular Disease. In the UAB study, African Americans comprised 55.6 percent of those who had COVID-19 and stroke and 37.7 percent of those with only stroke.

Interestingly, in our patients with stroke and COVID-19, the neutrophil and lymphocyte levels were only borderline high and low, respectively, Lin said, yet the NLR was almost twice as high as in patients without COVID-19. This potentially indicates that the systemic inflammatory response triggered by COVID-19 can cascade from multiple components.

Co-authors with Lin for the study, Racial differences and an increased systemic inflammatory response are seen in patients with COVID-19 and ischemic stroke, are Yurany A. Arevalo, UAB Department of Neurology; Hely D. Nanavati, Department of Epidemiology, UAB School of Public Health; and Diana M. Lin, UAB Department of Pathology.

See the rest here:
Stroke patients with COVID-19 have increased inflammation, stroke severity and death - The Mix

UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology – Yahoo Finance

- Corporate restructuring to extend cash runway through mid-2022 and key milestones -

- UBX1325 to enter clinical development in patients with diabetic macular edema -

SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it has initiated a restructuring to align its resources on cellular senescence programs in ophthalmology and neurology while further extending operating capital. UNITY will advance UBX1325 to Phase 1 clinical development in patients with diabetic macular edema, and expects to dose the first patient in the second half of 2020, consistent with prior guidance.

UNITY has prioritized its portfolio and aligned resources to deliver on key development milestones and drive innovation:

Revised Financial Guidance

UNITY will reduce its workforce by approximately 30% to optimize capital allocation and align with key strategic priorities, resulting in an estimated 75 full-time employees by the end of the year. These steps to focus resources are expected to extend the cash runway through mid-2022, with current cash and cash equivalents projected to fund UNITY through key clinical data readouts for UBX1325 and IND-enabling studies for UBX1967.

"UNITY is a pioneer in the development of therapeutics targeting senescent cells at the crux of many age-related diseases, and we will continue to build on this scientific foundation as we advance our pipeline," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "At UNITY, we have an extraordinary team that has contributed greatly to the advancement of this field, and we are deeply grateful for the contributions that all of our employees have made. Moving forward we will have a leaner and more agile team, which is well-resourced to advance our pipeline programs to key milestones."

Dr. Ghosh added: We are excited about advancing UNITYs lead ophthalmology program, UBX1325, into clinical studies in patients with diabetic macular edema, an indication with a well-defined development path and objective endpoints. In addition, I see significant opportunities emerging from programs in our preclinical pipeline targeting ophthalmologic and neurologic disease. I look forward to using my experience leading drug discovery and development programs in these areas to advance the development of a new class of high efficacy therapies.

About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Forward-Looking Statements

This press release contains forward-looking statements including statements related to UNITYs understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to extend healthspan, including for ophthalmologic and neurologic disease, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for diabetic macular edema and other ophthalmological diseases, the expected timing of initial results of the Phase 1 study of UBX1325 in diabetic macular edema, the expected size of UNITYs workforce following the restructuring, the impact of the workforce reduction on UNITYs business, and UNITYs expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITYs most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the Securities and Exchange Commission on July 31, 2020, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Continue reading here:
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology - Yahoo Finance

Surgical Table Market Research Report by Technology, by Surgery Type, by Material, by End-use – Global Forecast to 2025 – Cumulative Impact of…

New York, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Surgical Table Market Research Report by Technology, by Surgery Type, by Material, by End-use - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05968803/?utm_source=GNW

The Global Surgical Table Market is expected to grow from USD 921.67 Million in 2019 to USD 1,592.67 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 9.54%.

Market Segmentation & Coverage:This research report categorizes the Surgical Table to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Technology, the Surgical Table Market studied across Electric, Hydraulic, and Manual.

Based on Surgery Type, the Surgical Table Market studied across Bariatric Surgical Table, General Surgical Table, Neurology Surgical Table, Orthopaedic Surgical Table, Specialty Surgical Table, and Urology Surgical Table.

Based on Material, the Surgical Table Market studied across Composite and Metal.

Based on End-use, the Surgical Table Market studied across Ambulatory Surgical Centers and Hospitals.

Based on Geography, the Surgical Table Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Surgical Table Market including AGA Sanittsartikel GmbH, ALVO Limited Liability Company Sp. k., Amtai Medical Equipment Inc, Berchtold GmbH & Co. KG, BRUMABA GmbH & Co. KG, Denyers International PTY, Eschmann Holdings Ltd, Getinge AB, Heal Force Bio-meditech Holdings Limited, Hill-Rom Holdings Inc, Infinium Medical, Lojer Oy, Merivaara Corp., Mizuho Medical Co. Ltd, Narang Medical Limited, S I Surgical Private Limited, Skytron LLC, Staan Bio-Med Engineering Private Limited, Steris PLC, and Stille AB.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Surgical Table Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Surgical Table Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Surgical Table Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Surgical Table Market?4. What is the competitive strategic window for opportunities in the Global Surgical Table Market?5. What are the technology trends and regulatory frameworks in the Global Surgical Table Market?6. What are the modes and strategic moves considered suitable for entering the Global Surgical Table Market?Read the full report: https://www.reportlinker.com/p05968803/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Original post:
Surgical Table Market Research Report by Technology, by Surgery Type, by Material, by End-use - Global Forecast to 2025 - Cumulative Impact of...

The Longevity Project Part 3: Investing toward access: High country hospitals spend millions to increase residents’ access to care – Steamboat Pilot…

Editors note: This is Part 3 of a four-part series on longevity in the High Country. The series is being produced in partnership with The Aspen Times, Vail Daily, Glenwood Post Independent, Summit Daily News and Steamboat Pilot & Today. Read more at SteamboatPilot.com/longevity.

STEAMBOAT SPRINGS Across the high country and Western Slope, hospitals during the past two decades have significantly increased their offerings to patients through adding specialized medicine, technology and facility upgrades.

Patients living in more isolated and rural communities are experiencing less of a need to drive to the Front Range or other metropolitan areas for certain surgeries, treatments and other specialty or emergency care.

At UCHealth Yampa Valley Medical Center, the list of expansions, additions and upgrades during the past 15 years is extensive, from the Gloria Gossard Breast Care Center in 2014 and the Jan Bishop Cancer Center in 2017, to the Level III trauma center designation in 2018 and the opening of the Steamboat Surgery Center in August, which the hospital operates in partnership with Steamboat Orthopaedic & Spine Institute.

Today, Yampa Valley Medical Center CEO Soniya Fidler said many second homeowners wait until their time in Steamboat Springs to schedule appointments.

We have some advanced technology unheard of even in larger cities, she said, also emphasizing improvements to patient experience and noting patients come to the hospital in Steamboat Springs from outlying areas that may be just as close in proximity to the Front Range.

And it goes beyond comfort and convenience. In the rare life-or-death situation, time spent on the road can play a deciding role in the outcome.

The Level 3 trauma center designation at the hospital has been huge, Fidler said.

The designation provides emergency care for people who would otherwise have been on a flight to Denver or Grand Junction. And with the addition of Telestroke technology, specialists are able to rule out strokes to prevent unnecessary transportation. From its implementation in the hospitals emergency department in November 2018, 123 patients have benefited from the technology.

Patients who had even a sign of stroke were often previously flown out, she said. But now, the quick access to a neurologist can provide an immediate, and more thorough, assessment.

On the flip side, people with special care needs, such as oncology, cardiology and chronic pain management, often choose where to live based on the services available within the area.

Fidler also observes travel time and ease of access can make the difference between patients getting non-emergent care and neglecting it.

Working to keep more patients in Steamboat a more geographically remote location is also enticing some to stay close to home instead of traveling to the Eagle or Roaring Fork valleys.

Many of Colorados recent leaps and strides toward better, more accessible health care were facilitated in part by the states expansion of Medicaid under the Affordable Care Act in 2013, said Cara Welch, the Colorado Hospital Association director of communications.

At Yampa Valley Medical Center, growth was already well underway, but the merger of the hospital in 2017 into the UCHealth network led to a more rapid expansion of offerings from the opening of the endocrinology and ear nose and throat clinics, in 2018 and 2019 respectively, to the 2020 addition of a midwifery program in theUCHealth Womens Care Clinic and the opening of a full-time neurology clinic and rheumatology clinic just in recent weeks.

The merger, referred by some community members as more of a takeover, was not without challenges. There was strong sentiment against the move from both hospital staff and community members over concerns of what a corporate union would do to the independent community hospital.

Several years later, it is unlikely all discontent has disappeared, but Fidler said on the recent marking of the three-year anniversary, the decision to seek out and choose a partnering organization has only been solidified.

Not only by the list of accomplishments, she said, but also in the past six months going through the unprecedented experience of a global pandemic.

There is a lot of pride in our workforce and community in being associated with UCHealth, Fidler said.

On the merger, UCHealth Communications Specialist Lindsey Reznicek added the move was made proactively to ensure the community maintained access to high quality care.

While there are rural hospitals struggling and closing in many parts of the country, a rural hospital has not closed in Colorado since the 1980s, according to the hospital associations data.

Reznicek said the timing of the merger was important to ensure the hospital in Steamboat had control of the decision and was an attractive partner. Fidler also pointed to the importance of making sure the values and mission were aligned between the two organizations.

Another expansion not without strife was the partnership with local orthopedic surgeons to open the new ambulatory surgery center. The negotiations took years and began with significant disagreement between hospital administrators, the community and the surgeons. Ultimately, the voices of the surgeons and community were elevated, and the process became much more amiable.

Of course, all of this expansion costs money, and that takes careful planning, Fidler said.

There is a certain profit margin we need to achieve, she explained. We have to ask: What do we need to reinvest back into the community, and what do we need to reinvest back into our facilitys growth and strategic planning?

At this time, cancer patients still have to travel for radiation and oncology treatments. Fidler said they are closely monitoring demand and need for that service and are planning for how to fund an addition when the numbers dictate enough business to make the investment sustainable.

The UCHealth merger gave a big infusion of cash with about $105 million in profit for the local hospital. From that, former CEO Frank May said in 2018 about $50 million went into strategic capital, $20 into the Yampa Valley Health Care Foundation and $35 million in IT integration and routine capital.

Fidler said philanthropy also plays a significant role. In 2012, for example, the simulation lab opened, thanks to the generosity of a donor. In the lab, physicians and staff are able to practice high acuity, low frequency care protocols, ensuring theyre ready for whatever patient need may arise, Reznicek described.

In terms of the concept of access to care, Fidler noted that it has a broad definition. It can be something basic like transportation, or a much bigger barrier, especially in the high country, ofcost. In Colorado, the mountain areas have the highest rates for insurance premiums in the state.

Fidler said the hospital is constantly working to reach more underserved populations, and it is very aware of the need for more local resources in the area of mental and behavioral health care.

Fidler noted the importance of the community health needs assessment, which takes place every three years, on informing decision-making on where to make investments. The assessment takes a deep dive into the data and involves a survey of the community and health professions.

It sets the base on how we decide what the community needs, Fidler said.

That also translates to investment priorities outside the hospital.

In June, Yampa Valley Medical Center Foundation awarded 14 nonprofits a total of $275,000 in grants from the Community Health Benefit Fund. The grant aligned with the funding priorities of access to health care, mental health and substance use disorder.

Keeping Colorados rural hospitals open is one of the best ways to ensure residents maintain a high level of access to care, Welch said.

Welch said community support and strong hospital leadership also played major roles in keeping Colorados hospitals open.

Collaboration of our hospitals as a system is another factor, Welch explained. At times, they may compete for some business, but they collaborate in a number of ways that benefits all the hospitals throughout the state.

Reznicek noted Yampa Valley Medical Center has been able to share best practices with bigger hospitals, while also benefitting from the experience and expertise of others.

A lot of the higher acuity specialty care does still tend to come to the Denver metro area, Welch said. But, all our hospitals have really focused on what services they need to provide their communities, so people dont have to travel as far.

Glenwood Post Independent reporter Ike Fredregill contributed to this article.

To reach Kari Dequine Harden, call 970-871-4205, email kharden@SteamboatPilot.com or follow her on Twitter @kariharden.

Link:
The Longevity Project Part 3: Investing toward access: High country hospitals spend millions to increase residents' access to care - Steamboat Pilot...